Prognoza

Nie mamy danych analityków dla tej spółki.

Wiadomości Przejdź do aktualności

Silo Pharma publishes preclinical Alzheimer data and reports progress on PTSD candidate

Silo Pharma announced the publication of preclinical studies on its Alzheimer drug candidate SPC-14 in the journal Alzheimer’s Research & Therapy, which showed positive effects in a mouse model. At the same time, the company reported positive safety data and ongoing studies for SPC-15 (PTSD) and a Notice of Allowance for an SPC-15 patent; it also received a NASDAQ notice for falling below the minimum bid price requirement. The research was conducted in cooperation with Columbia University, and Silo holds an exclusive license for SPC-14 from Columbia. » Więcej na de.investing.com
Bullet Blockchain announces partnership with Tangem to expand crypto wallet offering

Bullet Blockchain is partnering with Swiss hardware-wallet provider Tangem so Tangem users can access crypto trading and other services via Bullet’s network. The company is also integrating supply-chain solutions from Silo Technologies, emphasizes its patent position for Bitcoin ATMs, and is pursuing a four-pillar growth plan to expand its ATM network in the US. » Więcej na de.investing.com
Silo Pharma successfully completes dosing phase in FDA safety study for PTSD drug

Silo Pharma has completed the dosing phase of a seven-day FDA safety and toxicity study for its PTSD drug candidate SPC-15 and expects results within the next 60 days. The company has also received a patent approval for SPC-15, is working on further preclinical studies, and plans to invest up to $1 million in Bitcoin as part of its treasury reserves. Additionally, Silo Pharma has been notified by NASDAQ of non-compliance with the minimum bid price requirement and has until December 2025 to regain compliance. » Więcej na de.investing.com

Historyczne dywidendy Dywidendy

Wszystkie wskaźniki dywidendowe Wszystkie wskaźniki

W 2022 roku Silo Wellness Aktie wypłaciła już 0,0471 € dywidend. Ostatnia wypłata nastąpiła w marzec 2022.

Dane finansowe spółki

W ostatnim roku Silo Wellness Aktie osiągnęła przychody w wysokości 339,66 tys. € i zysk netto w wysokości -5,88 mln €

(EUR)	2022	YoY
Przychody	339,66 tys.	226,83%
Zysk brutto	124,37 tys.	153,54%
Zysk netto	-5,88 mln	9,44%
EBITDA	-5,87 mln	11,42%

Dane fundamentalne

Wskaźnik	Wartość
Kapitalizacja rynkowa	1,5 mln €
Liczba akcji	154,48 mln
Maksimum/minimum z 52 tygodni	0,00971 € - 0,00971 €
Dywidendy	Nie
Beta	0,77
C/Z (PE Ratio)	-0,09
PEG (PEG Ratio)	0,00
C/WK (PB Ratio)	-0,10
C/S (PS Ratio)	3,32

Profil spółki

Silo Wellness Inc. ist ein Unternehmen für Psychedelika und Wellness und entwickelt psychedelische Medizin zur Traumabewältigung. Es entwickelt und vertreibt psilocybinfreie funktionelle Pilztinkturen und die Formulierung eines Psilocybin-Nasensprays in Jamaika. Außerdem bietet es ein Portfolio von funktionellen Pilzprodukten an: Psychedelische Wellness-Retreats in Jamaika und Oregon sowie der Anbau von psychedelischen Pilzen und Trüffeln in Jamaika; und die Entwicklung eines Smart Shops in Jamaika. Das Unternehmen war früher als Yukoterre Resources Inc. bekannt und änderte seinen Namen in Silo Wellness Inc. 26. Februar 2021. Der Hauptsitz von Silo Wellness Inc. befindet sich in Toronto, Kanada.